213Bi-[DOTA0, Tyr3]Octreotide Peptide Receptor Radionuclide Therapy of Pancreatic Tumors in a Preclinical Animal Model
Open Access
- 1 February 2006
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 12 (3), 897-903
- https://doi.org/10.1158/1078-0432.ccr-05-1264
Abstract
Purpose: The somatostatin analogue [DOTA0, Tyr3]octreotide (DOTATOC) has previously been labeled with low linear energy transfer (LET) β-emitters, such as 177Lu or 90Y, for tumor therapy. In this study, DOTATOC labeled with the high-LET α-emitter, 213Bi, was evaluated.Keywords
This publication has 29 references indexed in Scilit:
- Radioiodine and 211At-labeled guanidinomethyl halobenzoyl octreotate conjugates: potential peptide radiotherapeutics for somatostatin receptor-positive cancersPeptides, 2004
- Peptide Receptor Radionuclide TherapyAnnals of the New York Academy of Sciences, 2004
- Ac-225 and her daughters: the many faces of ShivaCell Death & Differentiation, 2002
- Immunohistochemical Localization of Somatostatin Receptor Type 2A in Rat and Human Tissues.Endocrine Journal, 2001
- Somatostatin and Its Receptor FamilyFrontiers in Neuroendocrinology, 1999
- Radioimmunotherapy with α-Particle Emitting RadioimmunoconjugatesActa Oncologica, 1996
- The feasibility of 225 Ac as a source of ??-particles in radioimmunotherapyNuclear Medicine Communications, 1993
- Distribution and Elimination of the Somatostatin Analogue (111In-DTPA-D-Phe1)-Octreotide (OctreoScan111)Acta Oncologica, 1993
- In vitro detection of somatostatin receptors in human tumorsMetabolism, 1992
- Biochemical and Functional Properties of Somatostatin ReceptorsJournal of Neurochemistry, 1992